{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:03:49Z","timestamp":1784901829686,"version":"3.55.0"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cutaneous leishmaniasis (CL) is a neglected tropical disease with limited accessible treatment options. Although pentavalent antimonials remain the gold standard, emergence of drug resistance and recurrent stockouts pose significant challenges. Amphotericin B is a well-established treatment of visceral leishmaniasis; however, its use in Old World CL (OWCL), particularly via the\u00a0intralesional route and using conventional formulations, has been studied only anecdotally to the best of our knowledge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the safety and efficacy of intralesional amphotericin B deoxycholate in the\u00a0treatment of OWCL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A nonrandomized prospective study was conducted to evaluate the safety and efficacy of intralesional amphotericin B in OWCL. All patients with CL who were treatment na\u00efve and with \u2264 5 skin lesions were included. Amphotericin B deoxycholate (2.5\u2005mg mL\u20131) was administered intralesionally at weekly intervals for up to 8 weeks, or until a complete clinical response, whichever occurred first. Treatment response was assessed at 4, 8 and 12 weeks. Treatment responders were followed for 6\u2005months to record recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 50 patients with 61 skin lesions were included in the analysis. At 12 weeks, 44 (88%) patients showed a\u00a0complete response and the overall cure rate was 96% (48\/50). Treatment response was not affected by the disease duration, lesion site or morphology. All treatment responders remained recurrence-free at the 6-month follow-up. Reported side effects were mild and self-limiting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Intralesional amphotericin B deoxycholate was found to be effective and safe in the treatment of OWCL. The study is limited by the small sample size, lack of a control group and nonavailability of species typing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llag136","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:24:58Z","timestamp":1773822298000},"page":"1458-1465","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of intralesional amphotericin B in the treatment of Old World cutaneous leishmaniasis: a nonrandomized open-label prospective study"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8409-331X","authenticated-orcid":false,"given":"Sabha","family":"Mushtaq","sequence":"first","affiliation":[{"name":"Department of Dermatology, Venereology & Leprology, Government Medical College, Kathua, University of Jammu , Jammu and Kashmir ,","place":["India"]},{"name":"Department of Dermatology, Venereology & Leprology, Government Medical College, Jammu, University of Jammu , Jammu and Kashmir ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devraj","family":"Dogra","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology & Leprology, Government Medical College, Jammu, University of Jammu , Jammu and Kashmir ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naina","family":"Dogra","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology & Leprology, Government Medical College, Jammu, University of Jammu , Jammu and Kashmir ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4634-6790","authenticated-orcid":false,"given":"Nafis","family":"Faizi","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Jawahar Lal Nehru Medical College, Aligarh Muslim University , Aligarh, Uttar Pradesh ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"2026072409172954400_llag136-B1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(07)70209-8","article-title":"Cutaneous leishmaniasis","volume":"7","author":"Reithinger","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"2026072409172954400_llag136-B2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s44197-024-00190-z","article-title":"Global dilemma and needs assessment toward achieving sustainable development goals in controlling leishmaniasis","volume":"14","author":"Bamorovat","year":"2024","journal-title":"J Epidemiol Glob Health"},{"key":"2026072409172954400_llag136-B3","author":"World Health Organization"},{"key":"2026072409172954400_llag136-B4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40257-015-0114-z","article-title":"Cutaneous leishmaniasis: recent developments in diagnosis and management","volume":"16","author":"de Vries","year":"2015","journal-title":"Am J Clin Dermatol"},{"key":"2026072409172954400_llag136-B5","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","article-title":"Leishmaniasis","volume":"392","author":"Burza","year":"2018","journal-title":"Lancet"},{"key":"2026072409172954400_llag136-B6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1365-2230.2001.00752.x","article-title":"Oral zinc sulfate in the treatment of acute cutaneous leishmaniasis","volume":"26","author":"Sharquie","year":"2001","journal-title":"Clin Exp Dermatol"},{"key":"2026072409172954400_llag136-B7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","article-title":"Drug resistance in leishmaniasis","volume":"19","author":"Croft","year":"2006","journal-title":"Clin Microbiol Rev"},{"key":"2026072409172954400_llag136-B8","first-page":"CD004834","article-title":"Interventions for American cutaneous and mucocutaneous leishmaniasis","volume":"2","author":"Gonzalez","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"2026072409172954400_llag136-B9","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1086\/515085","article-title":"U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis","volume":"28","author":"Meyerhoff","year":"1999","journal-title":"Clin Infect Dis"},{"key":"2026072409172954400_llag136-B10","first-page":"656523","article-title":"Efficacy of topical liposomal amphotericin B versus intralesional meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis","volume":"2011","author":"Layegh","year":"2011","journal-title":"J\u00a0Parasitol Res"},{"key":"2026072409172954400_llag136-B11","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/dth.12377","article-title":"Clinical response with intralesional amphotericin B in the treatment of Old World Cutaneous leishmaniasis: a preliminary report","volume":"29","author":"Mushtaq","year":"2016","journal-title":"Dermatol Ther"},{"key":"2026072409172954400_llag136-B12","volume-title":"Guideline for the Treatment of Leishmaniasis in the Americas","author":"Pan American Health Organization (PAHO)","edition":"2nd edn"},{"key":"2026072409172954400_llag136-B13","doi-asserted-by":"crossref","first-page":"e045707","DOI":"10.1136\/bmjopen-2020-045707","article-title":"Intravenous liposomal amphotericin B efficacy and safety for cutaneous and mucosal leishmaniasis: a systematic review and meta-analysis protocol","volume":"11","author":"Naeem","year":"2021","journal-title":"BMJ Open"},{"key":"2026072409172954400_llag136-B14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/pharmaceutics15010099","article-title":"Liposomal Amphotericin B for treatment of leishmaniasis: from the identification of critical physicochemical attributes to the design of effective topical and oral formulations","volume":"15","author":"Fr\u00e9zard","year":"2023","journal-title":"Pharmaceutics"},{"key":"2026072409172954400_llag136-B15","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0035-9203(01)90158-0","article-title":"Efficacious topical treatment for human cutaneous leishmaniasis with ethanolic lipid amphotericin B","volume":"95","author":"Vardy","year":"2001","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2026072409172954400_llag136-B16","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archderm.135.7.856","article-title":"Topical amphotericin B for cutaneous leishmaniasis","volume":"135","author":"Vardy","year":"1999","journal-title":"Arch Dermatol"},{"key":"2026072409172954400_llag136-B17","first-page":"CD005067","article-title":"Interventions for Old World cutaneous leishmaniasis","volume":"11","author":"Heras-Mosteiro","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2026072409172954400_llag136-B18","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s12879-016-1663-3","article-title":"Efficacy of cryotherapy for the treatment of cutaneous leishmaniasis: meta-analyses of clinical trials","volume":"16","author":"L\u00f3pez-Carvajal","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2026072409172954400_llag136-B19","doi-asserted-by":"crossref","first-page":"e0122569","DOI":"10.1371\/journal.pone.0122569","article-title":"Efficacy of thermotherapy to treat cutaneous leishmaniasis: a meta-analysis of controlled clinical trials","volume":"10","author":"Cardona-Arias","year":"2015","journal-title":"PLOS ONE"},{"key":"2026072409172954400_llag136-B20","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1371\/journal.pntd.0000381","article-title":"Efficacy of topical paromomycin in cutaneous leishmaniasis: a meta-analysis of randomized controlled trials","volume":"3","author":"Kim","year":"2009","journal-title":"PLOS Negl Trop Dis"},{"key":"2026072409172954400_llag136-B21","first-page":"1170","article-title":"Successful treatment of antimony-resistant cutaneous leishmaniasis with imiquimod and antimony combination","volume":"357","author":"Arevalo","year":"2001","journal-title":"Lancet"},{"key":"2026072409172954400_llag136-B22","first-page":"1139","article-title":"Topical imiquimod in combination with intralesional meglumine antimoniate in cutaneous leishmaniasis","volume":"50","author":"Salmanpour","year":"2011","journal-title":"Int J Dermatol"},{"key":"2026072409172954400_llag136-B23","first-page":"70","article-title":"Antileishmanial and cytotoxic effects of podophyllin and its derivatives","volume":"18","author":"Mahmoudvand","year":"2015","journal-title":"Iran J Basic Med Sci"},{"key":"2026072409172954400_llag136-B24","first-page":"1075808","article-title":"Field efficacy of topical nano-liposomal amphotericin B in cutaneous leishmaniasis","volume":"4","author":"Alizadeh","year":"2023","journal-title":"Front Trop Dis"},{"key":"2026072409172954400_llag136-B25","doi-asserted-by":"crossref","first-page":"e0184777","DOI":"10.1371\/journal.pone.0184777","article-title":"Efficacy of pentavalent antimoniate intralesional infiltration in the treatment of cutaneous leishmaniasis: a meta-analysis","volume":"12","author":"Brito","year":"2017","journal-title":"PLOS ONE"},{"key":"2026072409172954400_llag136-B26","first-page":"148","article-title":"Comparison of intralesional hypertonic saline and intralesional sodium stibogluconate in cutaneous leishmaniasis","volume":"21","author":"Salmanpour","year":"2010","journal-title":"J Dermatolog Treat"},{"key":"2026072409172954400_llag136-B27","first-page":"73","article-title":"Intralesional injection of 2% zinc sulfate solution in the treatment of acute Old World cutaneous leishmaniasis: a randomized, double-blind, controlled clinical trial","volume":"4","author":"Iraji","year":"2005","journal-title":"J Drugs Dermatol"},{"key":"2026072409172954400_llag136-B28","first-page":"682","article-title":"Comparative study of intralesional metronidazole versus sodium stibogluconate in Old World cutaneous leishmaniasis","volume":"30","author":"Salmanpour","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"2026072409172954400_llag136-B29","first-page":"1093","article-title":"Intralesional metronidazole in the treatment of cutaneous leishmaniasis: a clinical trial","volume":"55","author":"Salmanpour","year":"2016","journal-title":"Int J Dermatol"},{"key":"2026072409172954400_llag136-B30","doi-asserted-by":"crossref","first-page":"1091709","DOI":"10.3389\/fpubh.2023.1091709","article-title":"Cutaneous leishmaniasis in the Islamic Republic of Iran: situation analysis and control strategies","volume":"11","author":"Sharifi","year":"2023","journal-title":"Front Public Health"},{"key":"2026072409172954400_llag136-B31","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00436-007-0638-0","article-title":"Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs","volume":"101","author":"Hadighi","year":"2007","journal-title":"Parasitol Res"},{"key":"2026072409172954400_llag136-B32","first-page":"156","article-title":"The efficacy, relapse and failure in the treatment of anthroponotic cutaneous leishmaniasis with intralesional glucantime along with cryotherapy","volume":"23","author":"Karvar","year":"2016","journal-title":"J\u00a0Kerman Univ MedSci"},{"key":"2026072409172954400_llag136-B33","doi-asserted-by":"crossref","first-page":"e0217683","DOI":"10.1371\/journal.pone.0217683","article-title":"A clinical study of cutaneous leishmaniasis in a new focus in the Kurdistan Region, Iraq","volume":"14","author":"Hussein","year":"2019","journal-title":"PLOS ONE"},{"key":"2026072409172954400_llag136-B34","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ijid.2003.10.006","article-title":"Cutaneous leishmaniasis: a 46-year study of epidemiology and clinical features in Saudi Arabia","volume":"8","author":"Al-Tawfiq","year":"2004","journal-title":"Int J Infect Dis"},{"key":"2026072409172954400_llag136-B35","first-page":"e0006006","article-title":"Efficacy of oral miltefosine compared with meglumine antimoniate in cutaneous leishmaniasis patients of Pakistan: a prospective, open-label, observational study","volume":"11","author":"Khan","year":"2017","journal-title":"PLOS Negl Trop Dis"},{"key":"2026072409172954400_llag136-B36","doi-asserted-by":"crossref","first-page":"e0244787","DOI":"10.1371\/journal.pone.0259009","article-title":"Treatment failure to sodium stibogluconate in cutaneous leishmaniasis: a prospective study from Sri Lanka","volume":"16","author":"Silva","year":"2021","journal-title":"PLOS ONE"},{"key":"2026072409172954400_llag136-B37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40121-020-00382-7","article-title":"Sixty years of amphotericin B: an overview of the main antifungal agent used to treat invasive fungal infections","volume":"10","author":"Cavassin","year":"2021","journal-title":"Infect Dis Ther"},{"key":"2026072409172954400_llag136-B38","doi-asserted-by":"crossref","first-page":"6627","DOI":"10.1128\/AAC.03570-14","article-title":"The production of reactive oxygen species is a universal action mechanism of amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug","volume":"58","author":"Mesa-Arango","year":"2014","journal-title":"Antimicrob. Agents Chemother"},{"key":"2026072409172954400_llag136-B39","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.bbrc.2010.07.099","article-title":"Amphotericin B inhibits entry of Leishmania donovani into primary macrophages","volume":"399","author":"Paila","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"2026072409172954400_llag136-B40","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1128\/AAC.42.12.3092","article-title":"Efficacious topical treatment for murine cutaneous leishmaniasis with ethanolic formulations of amphotericin B","volume":"42","author":"Frankenburg","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2026072409172954400_llag136-B41","doi-asserted-by":"crossref","first-page":"8029","DOI":"10.1016\/j.biomaterials.2011.07.021","article-title":"Accelerated healing of cutaneous leishmaniasis in nonhealing BALB\/c mice using water soluble amphotericin B-polymethacrylic acid","volume":"32","author":"Corware","year":"2011","journal-title":"Biomaterials"},{"key":"2026072409172954400_llag136-B42","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.4269\/ajtmh.2010.10-0171","article-title":"Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis","volume":"83","author":"Wortmann","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"2026072409172954400_llag136-B43","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1468-3083.2010.03908.x","article-title":"Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica","volume":"25","author":"Solomon","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026072409172954400_llag136-B44","doi-asserted-by":"crossref","first-page":"631","DOI":"10.4103\/0019-5154.143571","article-title":"Efficacy of intralesional amphotericin B for the treatment of cutaneous leishmaniasis","volume":"59","author":"Goyonlo","year":"2014","journal-title":"Indian J Dermatol"},{"key":"2026072409172954400_llag136-B45","first-page":"99","article-title":"A case of periocular plaque-type cutaneous leishmaniasis successfully treated with intralesional amphotericin B","volume":"2","author":"Stingeni","journal-title":"Clin Dermatol"},{"key":"2026072409172954400_llag136-B46","doi-asserted-by":"crossref","first-page":"627","DOI":"10.4103\/idoj.IDOJ_470_18","article-title":"Intralesional amphotericin B in the treatment of cutaneous leishmaniasis: a randomized controlled trial","volume":"10","author":"Goswami","year":"2019","journal-title":"Indian Dermatol Online J"},{"key":"2026072409172954400_llag136-B47","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s40121-022-00602-2","article-title":"Treatment of cutaneous leishmaniasis and insights into species-specific responses: a narrative review","volume":"11","author":"Madusanka","year":"2022","journal-title":"Infect Dis Ther"},{"key":"2026072409172954400_llag136-B48","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.4269\/ajtmh.17-0162","article-title":"Case report: Old World mucosal leishmaniasis: report of five imported cases to the Hospital for Tropical Diseases, London, United Kingdom","volume":"97","author":"Patel","year":"2017","journal-title":"Am J Trop Med Hyg"},{"key":"2026072409172954400_llag136-B49","doi-asserted-by":"crossref","first-page":"e7234","DOI":"10.1002\/ccr3.7234","article-title":"Oral mucosal leishmaniasis presenting as a nonhealing chronic oral growth: a case report","volume":"11","author":"Bajgai","year":"2023","journal-title":"Clin Case Rep"},{"key":"2026072409172954400_llag136-B50","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3201\/eid3009.231595","article-title":"Emerging Leishmania donovani lineages associated with cutaneous leishmaniasis, Himachal Pradesh, India, 2023","volume":"30","author":"Lypaczewski","year":"2024","journal-title":"Emerg Infect Dis"},{"key":"2026072409172954400_llag136-B51","doi-asserted-by":"crossref","first-page":"e07282","DOI":"10.1016\/j.heliyon.2021.e07282","article-title":"Typical and atypical cutaneous leishmaniasis in Himachal Pradesh (India)","volume":"7","author":"Lata","year":"2021","journal-title":"Heliyon"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag136\/67386362\/llag136.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/8\/1458\/67386362\/llag136.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/8\/1458\/67386362\/llag136.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:17:41Z","timestamp":1784899061000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/8\/1458\/8527082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":51,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,3,18]]},"published-print":{"date-parts":[[2026,7,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llag136","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,3,18]]}}}